However, the group receiving the PA - RGDS - encapsulated hPSC - ECs showed better perfusion recovery, more robust and longer cell survival (> 10 months), and higher and
prolonged angiogenic and vascular incorporation capabilities than the bare hPSC - EC - injected group.
Furthermore, this study demonstrated that a biocompatible PA - RGDS nanomatrix gel substantially improved long - term survival of hPSC - ECs in an ischemic environment and improved neovascularization effects of hPSC - ECs via
prolonged and unique
angiogenic and vessel - forming properties.